---
layout: post
title: "Prospective Grant of an Exclusive Patent License: Mutant IDH1 Inhibitors Useful for Treating Cancer"
date: 2026-02-05 18:57:24 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-24229
original_published: 2023-11-02 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of an Exclusive Patent License: Mutant IDH1 Inhibitors Useful for Treating Cancer

**Published:** February 05, 2026 18:57 UTC
**Source:** Federal Register
**Original Published:** November 02, 2023 00:00 UTC
**Document Number:** 2023-24229

## Summary

The National Center for Advancing Translational Sciences, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this Notice to Platform Pharmaceuticals, Inc. ("Platform Pharma"), headquartered in New York, NY.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/11/02/2023-24229/prospective-grant-of-an-exclusive-patent-license-mutant-idh1-inhibitors-useful-for-treating-cancer)
- API: https://www.federalregister.gov/api/v1/documents/2023-24229

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
